Consensus Akeso, Inc.

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-17 am EDT			5-day change	1st Jan Change
48.7 ^HKD	-2.01%		-2.50%	+4.96%

Apr. 24	Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	MT
Apr. 24	National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	CI

b.4E2Zz9qmb4AZ_kx2kunPtWfHwGj0ZsO0ENq4LxFnqZg.iifyhbD5J-0vsT0wy9Gr_VOygVnCB7TXYbPpZ3g12tDWG8GnqOImyyqYKw~2a5e790920420cc718edb33ca928a62a

Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	Feb. 23	MT
Nomura Adjusts Akeso's Price Target to HK$48.84 From HK$50.14, Keeps at Buy	23-07-26	MT
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy	23-02-23	MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy	22-12-07	MT
Nomura Adjusts Akeso's Price Target to HK$31.54 From HK$35.81, Keeps at Buy	22-08-24	MT
UBS Adjusts Akeso’s Price Target to HK$26.68 From HK$29.60, Keeps at Buy	22-06-08	MT
UBS Adjusts Akeso’s Price Target to HK$29.60 From HK$32.40, Keeps at Buy	22-04-05	MT
Nomura Adjusts Akeso's Price Target to HK$35.81 From HK$53.66, Keeps at Buy	22-04-01	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.08 CNY

Average target price

55.45 CNY

Spread / Average Target

+22.99%

High Price Target

63.52 CNY

Spread / Highest target

+40.91%

Low Price Target

45.74 CNY

Spread / Lowest Target

+1.45%

Nomura
UBS

Trading Rating

Investor Rating

ESG Refinitiv

B-